Teva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) have earned an average rating of “Hold” from the thirty-four analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $19.96.

TEVA has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Teva Pharmaceutical Industries from a “strong sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Cantor Fitzgerald set a $18.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Oppenheimer reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 4th. Mizuho upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $19.12 to $23.00 in a research note on Tuesday. Finally, Leerink Swann initiated coverage on shares of Teva Pharmaceutical Industries in a research note on Tuesday, January 2nd. They issued an “underperform” rating and a $15.00 price objective for the company.

Shares of Teva Pharmaceutical Industries (NYSE TEVA) traded up $0.25 during mid-day trading on Tuesday, hitting $19.37. 19,467,736 shares of the stock traded hands, compared to its average volume of 25,560,000. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. Teva Pharmaceutical Industries has a 12 month low of $10.85 and a 12 month high of $37.94. The stock has a market cap of $19,830.00, a price-to-earnings ratio of -3.30, a P/E/G ratio of 1.36 and a beta of 0.54.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were issued a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.76%. The ex-dividend date was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is currently -12.27%.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. lifted its stake in Teva Pharmaceutical Industries by 7.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 241,571 shares of the company’s stock worth $8,025,000 after purchasing an additional 17,116 shares during the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Teva Pharmaceutical Industries by 1.5% in the second quarter. State Board of Administration of Florida Retirement System now owns 42,611 shares of the company’s stock worth $1,416,000 after purchasing an additional 611 shares during the last quarter. Prudential Financial Inc. lifted its stake in Teva Pharmaceutical Industries by 0.9% in the second quarter. Prudential Financial Inc. now owns 77,973 shares of the company’s stock worth $2,590,000 after purchasing an additional 730 shares during the last quarter. Principal Financial Group Inc. lifted its stake in Teva Pharmaceutical Industries by 21.1% in the second quarter. Principal Financial Group Inc. now owns 124,174 shares of the company’s stock worth $4,125,000 after purchasing an additional 21,658 shares during the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. bought a new stake in Teva Pharmaceutical Industries in the second quarter worth $6,560,000. 51.98% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “Teva Pharmaceutical Industries Ltd (TEVA) Receives Consensus Recommendation of “Hold” from Brokerages” was reported by Markets Daily and is owned by of Markets Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.themarketsdaily.com/2018/01/10/teva-pharmaceutical-industries-ltd-teva-receives-consensus-recommendation-of-hold-from-brokerages.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply